Journal article
Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review
Abstract
Second-line treatment options are limited for patients with advanced non-small-cell lung cancer (NSCLC). Standard therapy includes the cytotoxic agents docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiologic response rates and have been well tolerated. The objective of this …
Authors
Ellis PM; Vella ET; Ung YC
Journal
Clinical Lung Cancer, Vol. 18, No. 5, pp. 444–459.e1
Publisher
Elsevier
Publication Date
September 2017
DOI
10.1016/j.cllc.2017.02.001
ISSN
1525-7304
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoplasm StagingNivolumabProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as TopicSurvival Rate